A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

Inclusion Criteria:

• Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task ForceCriteria (TFC)

• Documentation of a pathogenic or likely pathogenic truncating variant in PKP2

• Frequent premature ventricular contractions (PVCs)

• Patients must have an ICD placed prior to enrollment

• Left ventricular ejection fraction (LVEF) ≥ 50% for Part A participants. Leftventricular ejection fraction (LVEF) ≥40% for Part B participants.

Exclusion Criteria:

• Evidence of variant(s) in addition to PKP2 that meet standard criteria to beconsidered pathogenic or likely pathogenic for an arrhythmogenic cardiomyopathy.

• A history of other cardiac abnormalities as specified in the protocol.

• New York Heart Association symptoms of heart failure of Class IV at the time ofconsent.

• A history of prior gene transfer therapy.